Influence of marker of insulin resistance upon HCV treatment responses to PEG Intron and Rebetol therapy

Trial Profile

Influence of marker of insulin resistance upon HCV treatment responses to PEG Intron and Rebetol therapy

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2006

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top